Vaccines, Immunoprophylaxis, and Immunotherapy for Coronaviruses

冠状病毒的疫苗、免疫预防和免疫治疗

• 批准号: 8946543
• 负责人: Kanta Subbarao
• 金额: $ 26.27万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8946543
• 关键词: Animal Model; Cessation of life; Coronavirus; Country; Development; Dipeptidyl Peptidases; Disease; Disease Outbreaks; Evaluation; Ferrets; Goals; Immune response; Immunotherapeutic agent; Immunotherapy; Inbred BALB C Mice; Infection; London; Mesocricetus auratus; Middle East; Modeling; Mouse Strains; Mus; Names; Oryctolagus cuniculus; Pathogenesis; Patients; Prevention strategy; Respiratory System; Respiratory tract structure; Syndrome; Vaccines; Virus; Virus Receptors; aged; immunoprophylaxis; novel; prevent; respiratory; treatment strategy

MERS-CoV strains, including EMC and London strains, reportedly do not replicate in the respiratory tract of various strains of mice, including BALB/c, C57BL/6, and STAT 1-/-, or in aged (12- to 14-months old) BALB/c mice, or in 5-weeks-old golden Syrian hamsters or in ferrets. The receptor for the virus has been identified as a dipeptidyl peptidase 4. We are evaluating the ability of MERS-CoV to infect and replicate in rabbits, in order to develop a model that can be used to study the pathogenesis and immune response to the novel coronavirus. It is not known whether the novel coronavirus can replicate and cause disease in this species.

MERS-CoV毒株，包括EMC和London毒株，据报道不会在包括BALB/c、C57BL/6和STAT 1/-在内的各种品系的小鼠的呼吸道中复制，也不会在12至14个月大的BALB/c小鼠、5周大的金色叙利亚仓鼠或雪貂中复制。该病毒的受体已被鉴定为二肽基肽酶4。我们正在评估MERS冠状病毒在兔体内感染和复制的能力，以建立一种可用于研究新型冠状病毒致病机理和免疫应答的模型。目前尚不清楚这种新型冠状病毒是否能在该物种中复制并导致疾病。